Literature DB >> 21078458

Antiretroviral pharmacology: special issues regarding pregnant women and neonates.

Mark Mirochnick1, Brookie M Best, Diana F Clarke.   

Abstract

Antiretrovirals may be used in pregnant women infected with the HIV and their newborns both for treatment of maternal HIV disease and for prevention of mother-to-child transmission of HIV. More than 25 antiretroviral agents in 5 classes have been approved, with new drugs and classes in development. This article reviews current knowledge of the pharmacology of these drugs during pregnancy and in the newborn period, highlighting those pharmacologic issues critical to the safe and effective use of antiretrovirals in these populations.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21078458     DOI： 10.1016/j.clp.2010.08.006

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN： 0095-5108            Impact factor:   3.430


  12 in total

1.  Effect of pregnancy on emtricitabine pharmacokinetics.

Authors:  A M Stek; B M Best; W Luo; E Capparelli; S Burchett; C Hu; H Li; J S Read; A Jennings; E Barr; E Smith; S S Rossi; M Mirochnick
Journal:  HIV Med       Date:  2011-11-30       Impact factor: 3.180

2.  World Health Organization generic protocol to assess drug-resistant HIV among children <18 months of age and newly diagnosed with HIV in resource-limited countries.

Authors:  Silvia Bertagnolio; Martina Penazzato; Michael R Jordan; Deborah Persaud; Lynne M Mofenson; Diane E Bennett
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

3.  Modelling the potential impact of providing preexposure prophylaxis in pregnant and breastfeeding women in South Africa.

Authors:  Dvora L Joseph Davey; Linda-Gail Bekker; Yolanda Gomba; Thomas Coates; Landon Myer; Leigh F Johnson
Journal:  AIDS       Date:  2019-07-01       Impact factor: 4.177

4.  Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.

Authors:  Alice Stek; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Sandra K Burchett; Regis Kreitchmann; Kittipong Rungruengthanakit; Tim R Cressey; Lynne M Mofenson; Elizabeth Smith; David Shapiro; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

Review 5.  Delivering preexposure prophylaxis to pregnant and breastfeeding women in Sub-Saharan Africa: the implementation science frontier.

Authors:  Dvora L Joseph Davey; Linda-Gail Bekker; Pamina M Gorbach; Thomas J Coates; Landon Myer
Journal:  AIDS       Date:  2017-10-23       Impact factor: 4.177

6.  Raltegravir in vitro effect on bilirubin binding.

Authors:  Diana F Clarke; Ronald J Wong; Larissa Wenning; David K Stevenson; Mark Mirochnick
Journal:  Pediatr Infect Dis J       Date:  2013-09       Impact factor: 2.129

7.  Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.

Authors:  Angela M Bengtson; Brian W Pence; Ellen F Eaton; Jessie K Edwards; Joseph J Eron; William C Mathews; Katie Mollan; Richard D Moore; Connall O'Cleirigh; Elvin Geng; Michael J Mugavero
Journal:  Antivir Ther       Date:  2018

Review 8.  Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

Authors:  Kajal Buckoreelall; Tim R Cressey; Jennifer R King
Journal:  Clin Pharmacokinet       Date:  2012-10-01       Impact factor: 5.577

9.  Antiretroviral therapy, pregnancy, and birth defects: a discussion on the updated data.

Authors:  Luiz Euribel Prestes-Carneiro
Journal:  HIV AIDS (Auckl)       Date:  2013-08-01

10.  Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.

Authors:  Nikki Mulligan; Stein Schalkwijk; Brookie M Best; Angela Colbers; Jiajia Wang; Edmund V Capparelli; José Moltó; Alice M Stek; Graham Taylor; Elizabeth Smith; Carmen Hidalgo Tenorio; Nahida Chakhtoura; Marjo van Kasteren; Courtney V Fletcher; Mark Mirochnick; David Burger
Journal:  Front Pharmacol       Date:  2016-08-04       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.